TY - JOUR T1 - Secondary malignancies in long-term ovarian cancer survivors: results of the ‘Carolin meets HANNA’ study JF - International Journal of Gynecologic Cancer JO - Int J Gynecol Cancer SP - 709 LP - 712 DO - 10.1136/ijgc-2020-002155 VL - 31 IS - 5 AU - Hannah Woopen AU - Carolin Rolf AU - Elena Ioana Braicu AU - Nina Buttmann-Schweiger AU - Benjamin Barnes AU - Joanna Baum AU - Klaus Pietzner AU - Klaus Kraywinkel AU - Jalid Sehouli Y1 - 2021/05/01 UR - http://ijgc.bmj.com/content/31/5/709.abstract N2 - Objective To evaluate the rate of secondary malignancies in long-term survivors with ovarian cancer.Methods Long-term survivors with ovarian cancer (survival ≥8 years after initial diagnosis) with multiple malignancies were identified within the Tumorbank Ovarian Cancer and our study ‘Carolin meets HANNA – Holistic Analyses of Long-term Survivors with Ovarian Cancer’.Results Of a total of 225 long-term survivors with ovarian cancer, 36 patients (16%) had at least one more cancer diagnosis before, concomitant with, or after, ovarian cancer. Median age was 52.5 years (range 37–79). A total of 60% were diagnosed with stage III/IV and most tumors were high-grade (88.6%), as well as of serous histology (63.9%). Median overall survival was 10 years (range 8–19). Secondary cancer after ovarian cancer was found in 17 long-term survivors (7.6%). Breast cancer was the most frequent secondary malignancy. Median duration between diagnosis of primary ovarian cancer and secondary cancer diagnosis was 78.5 months (range 12–220). BRCA was tested in 11 patients with seven patients being BRCA1 and one patient BRCA2 positive. Secondary cancers were detected by screening in 35.3% and self-detected in 29.4% of patients (breast self-examination).Conclusion A secondary malignancy was diagnosed in 7.6% of long-term survivors. Routine follow-up and cancer screening should be performed in long-term ovarian cancer survivors.Data are available upon reasonable request from HW (hannah.woopen@charite.de). ER -